NCEL
NewcelX Ltd.
NASDAQ · CHHealthcareBiotechnology
$3.97-2.93%
Price as of Jul 20, 2026
NCEL financials
NewcelX Ltd. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $3.3K | $11.4K | $11.4K |
| Gross profit | $0.00 | -$3.3K | -$11.4K | -$11.4K |
| Operating expenses | $2.5M | $4.4M | $11.8M | $15.5M |
| Operating income | -$2.5M | -$4.4M | -$11.8M | -$15.5M |
| Net income | -$8.3M | -$2.0M | -$12.2M | -$16.5M |
| EBITDA | -$2.2M | -$3.6M | -$11.8M | -$15.5M |
| Basic EPS | $-2.16 | $-26.30 | $-3.20 | $-8.40 |
| Diluted EPS | $-2.16 | $-26.30 | $-3.20 | $-8.40 |
| Balance sheet | ||||
| Cash & equivalents | $2.2M | $1.7M | $897.7K | $8.9M |
| Total assets | $11.4M | $2.2M | $1.8M | $9.3M |
| Total liabilities | $4.2M | $826.8K | $10.7M | $6.0M |
| Stockholders’ equity | $7.3M | $1.4M | -$8.8M | $3.3M |
| Total debt | $355.0K | $0.00 | $1.6M | $0.00 |
| Net debt | -$1.8M | -$1.7M | $736.1K | -$8.9M |
| Cash flow | ||||
| Operating cash flow | -$2.8M | -$4.3M | -$9.7M | -$13.9M |
| Capital expenditure | -$8.0K | -$3.9K | -$4.00 | $0.00 |
| Free cash flow | -$2.8M | -$4.3M | -$9.7M | -$13.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |